To print: Select File and then Print from your browser's menu

Title: FDA Approves Diaphragm-Pacing Device

"FDA Approves Diaphragm-Pacing Device"

NEW YORK -- June 18, 2008 -- The US Food and Drug Administration (FDA) announced today that it approved the NeuRx RA/4 Diaphragm Pacing System (DPS), an implantable electronic device that stimulates the diaphragm and allows certain patients with spinal cord injury to breathe for at least 4 hours a day without a mechanical ventilator. "While the NeuRx RA/4 does not cure paralysis of the diaphragm, allowing patients to be free from a mechanical ventilator for at least 4 hours a day may enhance their quality of life," said Daniel G. Schultz, MD, Center for Devices and Radiological Health, FDA, Rockville, Maryland. The NeuRx DPS RA/4 uses 4 electrodes implanted in the muscle of the diaphragm to electronically stimulate contraction, thus allowing the patient to inhale. The FDA approved the distribution of this device under a Humanitarian Device Exemption, an approval process for devices intended to treat or diagnose conditions that affect fewer than 4,000 people per year. In a multicentre trial, the device has been demonstrated to be safe and to have probable benefit to the patient by allowing at least 4 hours per day of freedom from a mechanical ventilator. SOURCE: US Food and Drug Administration

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.